Shenzhen Hepalink Pharmaceutical Group News

Hyperui: Announcement of Shenzhen Haipuri Pharmaceutical Group Co., Ltd. on interest payment, redemption results and delisting of the “22 Hyperui” corporate bonds

Mar 28 19:49

Haipry: SDIC Securities Co., Ltd.\'s temporary fiduciary management affairs report on the pre-loss of the 2023 annual performance of Shenzhen Haipuri Pharmaceutical Group Co., Ltd.

Feb 6 19:35

Haipuri: Report of SDIC Securities Co., Ltd. on the temporary fiduciary management affairs of the Shenzhen Securities Regulatory Bureau\'s decision to order corrective measures against Shenzhen Haipuri Pharmaceutical Group Co., Ltd.

Feb 6 19:35

Haipuri: Report of SDIC Securities Co., Ltd. on important matters of the subsidiary of Shenzhen Haipuri Pharmaceutical Group Co., Ltd. and the receipt of a letter of regulatory concern

Jan 18 18:19

Haipuri: Anxin Securities Co., Ltd.\'s temporary fiduciary management affairs report on the decline in the performance of Shenzhen Haipuri Pharmaceutical Group Co., Ltd. for the third half year of 2023

Sep 6, 2023 17:45

Haipuri: Shenzhen Haipuri Pharmaceutical Group Co., Ltd. Corporate Bonds 2022 Fiduciary Management Report

Jun 30, 2023 16:13

Hepry: Shenzhen Hyperthery Pharmaceutical Group Co., Ltd. publicly issued corporate bonds to professional investors in 2023 tracking rating report

May 25, 2023 19:47

Hypertherm: Announcement on the public issuance of corporate bonds to professional investors by Shenzhen Haipuri Pharmaceutical Group Co., Ltd. in 2022 for the 2023 annual interest payment announcement

Mar 29, 2023 19:46

Hypertherm: Announcement of Shenzhen Hyprei Pharmaceutical Group Co., Ltd. on the “20 Hyperpuri” resale results and delisting

Feb 23, 2023 17:26

Hepry: Shenzhen Haipuri Pharmaceutical Group Co., Ltd. publicly issued corporate bonds (epidemic prevention and control bonds) to qualified investors in 2023 annual interest payment announcement in 2020

Feb 23, 2023 17:26

Hypertherm: Financial statements of Shenzhen Hi-Tech Investment Group Co., Ltd. for the first half year of 2022 (unaudited)

Aug 30, 2022 18:00

Hypertherm: 2021 Annual Equity Distribution Implementation Notice

Jul 21, 2022 00:00

Hepry: Shenzhen Haipuri Pharmaceutical Group Co., Ltd. publicly issued corporate bonds to qualified investors in 2020 (epidemic prevention and control bonds) 2021 regular fiduciary management affairs report

Jun 28, 2022 16:12

Hypertherm: Shenzhen Hypertherm Pharmaceutical Group Co., Ltd. 2022 Follow-up Rating Report

Jun 8, 2022 21:16

Hypertherm: Announcement on the public issuance of corporate bonds to professional investors by Shenzhen Hyperrui Pharmaceutical Group Co., Ltd. to professional investors in 2022 for listing on the Shenzhen Stock Exchange

Apr 8, 2022 17:20

Hypertherm: Announcement on the results of the public issuance of corporate bonds to professional investors by Shenzhen Hepry Pharmaceutical Group Co., Ltd. in 2022 (subject to this)

Apr 1, 2022 18:06

Hepry: Announcement on the results of the public issuance of corporate bonds to professional investors by Shenzhen Hyperthery Pharmaceutical Group Co., Ltd. in 2022

Apr 1, 2022 17:36

Hypertherm: Announcement on the coupon interest rate for the public issuance of corporate bonds to professional investors by Shenzhen Hyperrui Pharmaceutical Group Co., Ltd. in 2022

Mar 31, 2022 00:00

Hepry: Announcement on extending the bookkeeping and filing period for the public issuance of corporate bonds to professional investors by Shenzhen Hyperrui Pharmaceutical Group Co., Ltd. in 2022

Mar 30, 2022 19:30

Hepry: Announcement on extending the bookkeeping and filing period for the public issuance of corporate bonds to professional investors by Shenzhen Hyperrui Pharmaceutical Group Co., Ltd. in 2022

Mar 30, 2022 18:24